Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development

Autoimmun Rev. 2021 Feb;20(2):102742. doi: 10.1016/j.autrev.2020.102742. Epub 2020 Dec 14.

Abstract

Autoimmune rheumatic diseases (ARD) are characterized by systemic manifestations and multiple organ involvement, including the lung. Interstitial Lung Disease (ILD) is a cardinal manifestation of lung involvement in patients with ARD and is associated with significant morbidity and mortality. Corticosteroids and immunosuppressive drugs are used as first -line treatment. Targeted therapies, such as biological disease modifying antirheumatic drugs (DMARDS) and anti- fibrotic agents are new treatment options. In this review we discuss the role of targeted therapies in patients with ILD secondary to ARD.

Keywords: Anti-fibrotic treatment; Autoimmune rheumatic diseases; Interstitial lung disease; Myositis; Rheumatoid arthritis; Scleroderma immunosuppressive drugs; Sjögren's syndrome; Targeted treatment; Vasculitis.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Autoimmune Diseases* / complications
  • Autoimmune Diseases* / drug therapy
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lung Diseases, Interstitial* / complications
  • Lung Diseases, Interstitial* / drug therapy
  • Rheumatic Diseases* / complications
  • Rheumatic Diseases* / drug therapy

Substances

  • Antirheumatic Agents
  • Immunosuppressive Agents